FindTrial
Sign In

PP3M 350 mg eq.

DRUG3 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Schizophrenia

Phase 3

Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
CompletedNCT01515423
Janssen Research & Development, LLCSchizophrenia
Start: 2012-05-31End: 2015-03-31Updated: 2016-05-02
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
CompletedNCT01529515
Janssen Research & Development, LLCSchizophrenia
Start: 2012-05-31End: 2014-04-30Updated: 2016-05-11
A Study of Paliperidone Palmitate 6-Month Formulation
CompletedNCT03345342
Janssen Research & Development, LLCSchizophrenia
Start: 2017-11-20End: 2020-05-08Updated: 2025-04-29

Related Papers

Weight and metabolic changes in patients with schizophrenia treated with paliperidone palmitate 6-month formulation versus paliperidone palmitate 3-month formulation: a post-hoc analysis.
2026-09-01
Long-Term Symptomatic and Functional Remission with Paliperidone Palmitate 6-Monthly Treatment in Schizophrenia: A 3-Year Post-Hoc Analysis.
2025-06-18
Comparing two transitioning strategies to paliperidone palmitate once-every-6-months
CNS Spectrums2024-11-081 citations
Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).
2024-05-202 citations
Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I).
2024-05-151 citations
Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations
The International Journal of Neuropsychopharmacology2024-02-017 citations
Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia.
2024-01-083 citations
Importance of Long-Acting Injectable Antipsychotic Preparation, Administration, and Injection Site Tolerability: A Focus on Paliperidone Palmitate Once-Every-6-Months Formulation
Perspectives In Psychiatric Care2023-12-19
Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study
Medicine2023-08-253 citations
Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia
The International Journal of Neuropsychopharmacology2023-07-0314 citations
Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study.
2023-04-135 citations
A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia
The International Journal of Neuropsychopharmacology2021-11-1057 citations
Defining "Adequately Treated": A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate.
2021-01-063 citations
Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire.
2020-07-0242 citations
<p>Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies</p>
Neuropsychiatric Disease and Treatment2020-06-0119 citations
S208. COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF A PATIENT-REPORTED QUESTIONNAIRE FROM A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY
Schizophrenia Bulletin2020-04-01
<p>Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study</p>
Neuropsychiatric Disease and Treatment2020-03-017 citations
Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia
Early Intervention in Psychiatry2019-09-1321 citations
Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies
Brazilian Journal of Psychiatry2019-04-177 citations
S32. EFFICACY AND SAFETY OF PALIPERIDONE PALMITATE ONCE-MONTHLY IN PATIENTS WITH SCHIZOPHRENIA WITH LOW, MODERATE, AND HIGH RECENT DISEASE ACTIVITY AT BASELINE
Schizophrenia Bulletin2019-04-01

8 more papers not shown